Membranous Nephropathy When First-Line Immunosuppressive Therapy Has Not Achieved Remission

Clinical scenario

This protocol addresses membranous nephropathy in patients who have already completed a course of first-line immunosuppressive treatment but have not achieved the expected response. The situation calls for a defined second-line approach guided by the patient's prior therapy, tolerability, and response trajectory.

Previous treatment & failure condition

The prior line comprised immunosuppressive therapy selected by risk estimate — rituximab; or cyclophosphamide combined with alternate-month glucocorticoids; or a calcineurin inhibitor (CNI)-based regimen (cyclosporine or tacrolimus). The benchmark for success was complete or partial remission, defined by decreasing proteinuria, rising serum albumin, and disappearance of anti-PLA2R antibodies — assessed at 6 months from the start of therapy. Failure to reach these goals at that evaluation point is the trigger for this next-line protocol.

Treatment goals

Second-line therapy aims for a meaningful reduction in proteinuria alongside a measurable decline in anti-PLA2R antibody levels. When the chosen agent is rituximab, the protocol specifies that response is assessed at 3 months.

Approach (partial overview)

The second-line strategy centres on switching to, or repeating, an alternative immunosuppressive agent. The choice between available options is shaped by the patient's history with prior therapy, individual tolerability, and cumulative dose constraints — details the full protocol sets out explicitly. No dosages, sequencing, or eligibility criteria are shown here.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.kint.2021.05.015

Cyclophosphamide can be repeated; however, physicians must take into account the maximal tolerable dose: The cumulative dose should not exceed 10 g if preservation of fertility is required.
In patients who do not tolerate or can no longer use cyclophosphamide, rituximab could be offered.
When rituximab is chosen as second treatment, the response of proteinuria and anti-PLA2R antibodies should be evaluated after 3 months.

View source ↗